Literature DB >> 153149

Actin mediated release of ATP from a myosin-ATP complex.

J A Sleep, R L Hutton.   

Abstract

The apparent second-order rate constant, ka-2, of actin binding to a myosin-ATP state (M*.ATP) and releasing ATP to the medium has been determined by two methods. The first was the measurement of the amount of ATP released when actin was added to the intermediate state, M*.ATP; the second was the measurement of oxygen exchange between ATP and HOH. A quantitative treatment of ATP in equilibrium HOH exchange is given to allow extraction of elementary rate constants from the data. Agreement between the two methods was good and at low ionic strength and 23 degrees C, ka-2 is 6 X 10(5) M-1 s-1 which is about one-third the value of the apparent second-order rate constant, ka4, of actin binding to the myosin product state (M**.ADP.Pi). The determination of ka-2 allows a lower limit of 6 s-1 to be placed upon the first-order rate of ATP release from AM.ATP. This is to be compared with a value of less than or equal to 1.5 X 10(-4) s-1 for the equivalent steps of the myosin scheme; thus actin enhances the rate by a factor of 4 X 10(4) or more. A greater proportion of the bound ATP is released to the medium as ATP with increasing actin concentration. This reflects the contribution to rate limitation at saturating actin concentration of steps between myosin states dissociated from actin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 153149     DOI: 10.1021/bi00618a016

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  17 in total

1.  The M.ADP.Pi state is required for helical order in the thick filaments of skeletal muscle.

Authors:  S Xu; J Gu; T Rhodes; B Belknap; G Rosenbaum; G Offer; H White; L C Yu
Journal:  Biophys J       Date:  1999-11       Impact factor: 4.033

2.  Repriming the actomyosin crossbridge cycle.

Authors:  Walter Steffen; John Sleep
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

3.  Parallel inhibition of active force and relaxed fiber stiffness in skeletal muscle by caldesmon: implications for the pathway to force generation.

Authors:  B Brenner; L C Yu; J M Chalovich
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

4.  Involvement of weak binding crossbridges in force production in muscle.

Authors:  J M Chalovich; L C Yu; B Brenner
Journal:  J Muscle Res Cell Motil       Date:  1991-12       Impact factor: 2.698

5.  Mechanism of regulation of phosphate dissociation from actomyosin-ADP-Pi by thin filament proteins.

Authors:  David H Heeley; Betty Belknap; Howard D White
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-16       Impact factor: 11.205

6.  Velocity-dependent actomyosin ATPase cycle revealed by in vitro motility assay with kinetic analysis.

Authors:  Masaaki K Sato; Takashi Ishihara; Hiroto Tanaka; Akihiko Ishijima; Yuichi Inoue
Journal:  Biophys J       Date:  2012-08-22       Impact factor: 4.033

7.  Identification of functional differences between recombinant human α and β cardiac myosin motors.

Authors:  John C Deacon; Marieke J Bloemink; Heresh Rezavandi; Michael A Geeves; Leslie A Leinwand
Journal:  Cell Mol Life Sci       Date:  2012-02-16       Impact factor: 9.261

8.  The kinetics of magnesium adenosine triphosphate cleavage in skinned muscle fibres of the rabbit.

Authors:  M A Ferenczi; E Homsher; D R Trentham
Journal:  J Physiol       Date:  1984-07       Impact factor: 5.182

9.  Modification of the interactions of myosin with actin and 5'-adenylyl imidodiphosphate by substitution of ethylene glycol for water.

Authors:  S B Marston; R T Tregear
Journal:  Biochem J       Date:  1984-01-01       Impact factor: 3.857

10.  Erratum to: Identification of functional differences between recombinant human α and β cardiac myosin motors.

Authors:  John C Deacon; Marieke J Bloemink; Heresh Rezavandi; Michael A Geeves; Leslie A Leinwand
Journal:  Cell Mol Life Sci       Date:  2012-12       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.